On June 1, 2021 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, reported that results from twelve studies of selinexor, the world’s first approved oral selective inhibitor of nuclear export (SINE), were selected for the European Hematology Association (EHA) (Free EHA Whitepaper) Annual Congress, taking place in a virtual format on June 9 to 17 (Press release, Antengene, JUN 1, 2021, View Source [SID1234583350]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Selected Abstracts:
Phase 2 MARCH study of oral ATG-010 plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously exposed to an immunomodulatory agent and a proteasome inhibitor.
Abstract #: PB1670
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
Abstract #: S188
Selinexor containing regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies.
Abstract #: EP1002
Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed/refractory multiple myeloma (MM).
Abstract #: EP1008
Ciltacabtagene Autoleucel versus selinexor + dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) treated with ≥ 3 lines of prior therapy: A matching adjusted indirect comparison.
Abstract #: EP1049
Cost effectiveness comparison of belantamab mafodotin and selinexor in relapsed refractory multiple myeloma.
Abstract #: EP1173
Lymphocyte count effect on efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): A post-hoc analysis from phase 2B SADAL study.
Abstract #: EP530
Genomic correlates of respones to selinexor in multiple myeloma from the BOSTON study reveal a predictive signature.
Abstract #: EP936
Effects of selinexor on previously treated multiple myeloma (MM) with RAS-mutations.
Abstract #: EP966
Efficacy and safety of selinexor, bortezomib, and dexamethasone based on refractory status to lenalidomide in patients with previously treated multiple myeloma: A post-hoc analysis of the BOSTON study.
Abstract #: EP974
Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.
Abstract #: EP976
Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.
Abstract #: EP924